Tes Pharma Presents Last Results on TES-AKI-01 at the 62nd European Renal Association Congress in Wien

Jun 4, 2025

Tes Pharma Presents Results on TES-ONC-07 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 18, 2025

Professor Pellicciari awarded by President Mattarella with the Bronze Medal of Merit for Public Health

Apr 10, 2025

Tes Pharma Presents Last Results on TES-AKI-01 at the 30th Annual International Conference on Advances in Critical Care Nephrology

Feb 28, 2025

Tes Pharma Announces Appointment of Andrea Pellacani, MD, PhD, as Chief Medical Officer

Jan 29, 2025

Tes Pharma Announces Formation of AKI Clinical Advisory Board

Jan 21, 2025

Tes Pharma Announces Renewal of Research and Development Collaboration with Intercept Pharmaceuticals

Jan 14, 2025

Tes Pharma Announces Extension of its Series A Financing with Indaco Venture Partners

Dec 19, 2024

Scientific research agreement between Foro delle Arti Srl, TES Pharma Srl and Fondo XGEN Venture

Apr 10, 2024

Laboratory 4.0 of a Biotech Company

Feb 21, 2023

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

Nov 8, 2022

Prof. Roberto Pellicciari Recipient of the EFMC Honorary Fellow Award.

Aug 18, 2021

Research and Development of NAD+ modulators for the Treatment of Hepato-Renal Dysfunction in COVID-19 Patients

Jul 15, 2021

Pharmacological Modulation of NAD+ Homeostasis as a Novel Approach for the Treatment of Acute Kidney Disease

May 4, 2020

Integrated Platform for Research and Development of Innovative Drugs for Oncological and Metabolic Diseases

Mar 22, 2018